BiotechTube
Abbmira Therapeutics

Abbmira Therapeutics

Basel, Switzerland· Est.
abbmira.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Abbmira Therapeutics is an early-stage, private biotechnology company pioneering a novel approach to cancer immunotherapy by reprogramming the native immune system, specifically tumor-associated macrophages. The company's core technology is a small-molecule drug, Compound42, which targets a specific immune pathway to switch macrophages from a pro-tumor to an anti-tumor state. Operating from Basel, Switzerland, Abbmira is positioned in the competitive oncology space with a promising pre-clinical asset that could address limitations of current therapies. The company is actively seeking partnerships and investment to advance its lead program toward clinical development.

Oncology

Technology Platform

Small-molecule drugs designed to reprogram tumor-associated macrophages (TAMs) from a pro-tumor, immunosuppressive state to an anti-tumor, immunostimulatory state by targeting a specific immune pathway.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The large, unmet need in oncology for patients resistant to current immunotherapies creates a significant market for novel immune reprogramming approaches.
A successful small-molecule TAM reprogrammer could be used broadly as a combination therapy, enhancing the efficacy of existing standards of care.
The platform's potential may extend beyond oncology into inflammatory or fibrotic diseases where macrophage polarization plays a key role.

Risk Factors

High scientific risk associated with a novel, first-in-class mechanism that is unproven in human clinical trials.
Intense competition in the tumor microenvironment modulation space from companies with greater resources.
Financial risk as a pre-revenue, early-stage company dependent on future fundraising in a challenging capital environment.

Competitive Landscape

Abbmira operates in the competitive field of tumor microenvironment modulators, facing competition from companies developing antibodies against targets like CSF-1R, CD47, and CCR2. Its small-molecule approach differentiates it from many biologic competitors, potentially offering dosing and cost advantages. However, it must compete for investor attention and clinical validation against more advanced programs from both biotech and large pharmaceutical companies.

More companies in Immunotherapy / Immuno-Oncology →More companies in Switzerland →